Open AccessExcision repair cross-complementation group 1 codon 118 polymorphism, micro ribonucleic acid and protein expression, clinical outcome of the advanced gastric cancer response to first-line FOLFOX-4 in Qinghai-Tibetan plateau population
Author(s) -
Yujuan Qi,
Sen Cui,
Yingzhong Yang,
Jingqi Han,
Baojia Cai,
Cun-Fang Sheng,
Yan Ma,
Tana Wuren,
RiLi Ge
Publication year - 2013
Publication title -
journal of cancer research and therapeutics/journal of cancer research and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.475
H-Index - 39
eISSN - 0973-1482
pISSN - 1998-4138
DOI - 10.4103/0973-1482.119319
Subject(s) - ercc1 , oncology , biology , folfox , oxaliplatin , medicine , cancer research , gastroenterology , microbiology and biotechnology , genetics , cancer , gene , dna repair , colorectal cancer , nucleotide excision repair
The excision repair cross-complementation group 1 (ERCC1) codon 118 C/T polymorphism has been associated with clinical outcome in cancer patients treated with platinum chemotherapy. Ethnic differences in the frequency of this polymorphism have been observed in Caucasian and African populations.